The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback